Trillium Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Trillium Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41,223	Closed	-$572K	–	227
2022 Q1	$572K	Sell	41,223 -202	-0.5%	-$3.18K	0.02%	198
2021 Q4	$1.16M	Buy	41,425 +1,499	+4%	+$45.9K	0.03%	182
2021 Q3	$1.36M	Buy	39,926 +4,087	+11%	+$148K	0.04%	171
2021 Q2	$1.46M	Buy	35,839 +3,838	+12%	+$149K	0.04%	171
2021 Q1	$1.29M	Buy	+32,001	New	+$1.73M	0.04%	173

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Trillium Asset Management's ADPT Position: Q2 2022 in Review

Trillium Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 41,223 shares — an estimated $572K sold.

Trillium Asset Management first reported a position in ADPT in Q1 2021 and held it in 5 quarters. The position peaked at $1.46M in Q2 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

Trillium Asset Management reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
Trillium Asset Management sold 41,223 Adaptive Biotechnologies shares in Q2 2022, an estimated $572K.
Trillium Asset Management first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 5 quarters.
Trillium Asset Management's Adaptive Biotechnologies position peaked at $1.46M in Q2 2021.
209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Trillium Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.